Equities Analysts Set Expectations for SAGE Q3 Earnings

Sage Therapeutics, Inc. (NASDAQ:SAGE) – Analysts at Leerink Partnrs issued their Q3 2025 EPS estimates for shares of Sage Therapeutics in a research note issued to investors on Tuesday, February 11th. Leerink Partnrs analyst M. Goodman anticipates that the biopharmaceutical company will earn ($0.15) per share for the quarter. The consensus estimate for Sage Therapeutics’ current full-year earnings is ($6.46) per share. Leerink Partnrs also issued estimates for Sage Therapeutics’ FY2025 earnings at ($3.15) EPS, FY2026 earnings at ($1.75) EPS, FY2027 earnings at ($1.95) EPS, FY2028 earnings at ($1.55) EPS and FY2029 earnings at ($1.35) EPS.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) EPS for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%.

Other equities analysts also recently issued reports about the company. Oppenheimer decreased their price target on Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating for the company in a research note on Wednesday, October 30th. Needham & Company LLC reiterated a “hold” rating on shares of Sage Therapeutics in a research report on Wednesday. Scotiabank dropped their price target on Sage Therapeutics from $14.00 to $12.00 and set a “sector outperform” rating on the stock in a research report on Wednesday. TD Cowen decreased their price objective on shares of Sage Therapeutics from $10.00 to $9.00 and set a “hold” rating for the company in a report on Thursday, November 21st. Finally, Canaccord Genuity Group dropped their target price on shares of Sage Therapeutics from $9.00 to $8.00 and set a “hold” rating on the stock in a report on Wednesday. Three investment analysts have rated the stock with a sell rating, sixteen have given a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $9.65.

Sage Therapeutics Price Performance

Shares of SAGE stock opened at $7.18 on Friday. The firm has a fifty day moving average of $6.34 and a two-hundred day moving average of $6.93. Sage Therapeutics has a 1-year low of $4.62 and a 1-year high of $27.39.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of SAGE. RTW Investments LP lifted its holdings in Sage Therapeutics by 2.0% in the third quarter. RTW Investments LP now owns 5,591,700 shares of the biopharmaceutical company’s stock worth $40,372,000 after purchasing an additional 111,123 shares during the period. State Street Corp raised its position in shares of Sage Therapeutics by 18.2% during the 3rd quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company’s stock worth $21,127,000 after buying an additional 451,377 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Sage Therapeutics by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 1,256,903 shares of the biopharmaceutical company’s stock worth $6,827,000 after acquiring an additional 14,049 shares during the period. Federated Hermes Inc. boosted its holdings in shares of Sage Therapeutics by 63.7% in the fourth quarter. Federated Hermes Inc. now owns 1,105,779 shares of the biopharmaceutical company’s stock valued at $6,004,000 after acquiring an additional 430,432 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Sage Therapeutics by 2.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 462,309 shares of the biopharmaceutical company’s stock valued at $2,510,000 after acquiring an additional 10,116 shares during the period. Institutional investors own 99.22% of the company’s stock.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.